Cost-effectiveness of hypertension treatment
a population-based study
Keywords:
Cost-effectiveness, Hypertension, Treatment, Diuretics, Beta blockersAbstract
CONTEXT: The cost-effectiveness of the treatment of hypertension has scarcely been investigated in population-based studies. Most data come from secondary analysis of clinical trials and administrative sources. OBJECTIVE: To describe the healthcare costs for outpatient hypertension treatment in comparison with diabetes mellitus and chronic bronchitis, and to examine the cost-effectiveness of different classes of antihypertensive drugs. DESIGN: Cross-sectional population-based study. SETTING: Urban area of Pelotas, southern Brazil. PARTICIPANTS: Individuals aged 20-69 years, identified through multi-stage probability sampling. METHODS: Participants were interviewed at home. Demographic data, education, income, smoking, previous morbidity, use of medicine and other characteristics were assessed via a pre-tested questionnaire, and blood pressure while seated was measured in a standardized way. RESULTS: Approximately 24% of the participants had high blood pressure or were taking antihypertensive drugs, and among these, 33% had had a physician consultation during the month preceding the interview. The monthly mean costs of care for hypertension (R$ 89.90), diabetes (R$ 80.64) and bronchitis (R$ 92.63) were similar. Treatment of hypertension consumed 22.9% of the per-capita income, corresponding to R$ 392.76 spent per year exclusively on antihypertensive drugs. Most of the direct costs associated with hypertension and diabetes were spent on drugs, while patients with bronchitis had greater expenditure on appointments. The cost-effectiveness relationship was more favorable for diuretics (116.3) and beta blockers (228.5) than for ACE inhibitors (608.5) or calcium channel blockers (762.0). CONCLUSION: The costs of hypertension care are mainly dependent on the expenditure on blood pressure-lowering drugs. Treatment of hypertension with diuretics or beta blockers was more cost-effective than treatment with ACE inhibitors and calcium channel blockers.
Downloads
References
Fuchs FD, Moreira LB, Moraes RS, Bredemeier M, Cardozo SC. Prevalência de hipertensão arterial sistêmica e fatores associados na região urbana de Porto Alegre: estudo de base populacional. Arq Bras Cardiol 1995;63:473-9.
Piccini RX, Victora CG. Hipertensão arterial sistêmica em área urbana no sul do Brasil: prevalência e fatores de risco. Rev Saúde Pública 1994;28:261-7.
Bloch VB, Klein CH, Silva NAS, Nogueira AR, Campos LHS. Hipertensão arterial e obesidade na Ilha do Governador, Rio de Janeiro. Arq Bras Cardiol 1994;62:17-22.
Fuchs SC, Petter JG, Accordi M, et al. Estabelecendo a prevalência de hipertensão arterial sistêmica. Influência dos critérios de amostragem. Arq Bras Cardiol 2001;76:445-8.
Meissner I, Whisnant JP, Sheps SG, et al. Detection and control of high blood pressure in the community: do we need a wake- up call? Hypertension 1999;34:466-71.
Castiel LD. Inefetividade e ineficiência: reflexões sobre a epidemiologia e os serviços de saúde de um estado de mal estar social. Cad Saúde Públ 1990;61:27-39.
Johannesson M, Le Lorier J. How to assess the economics of hypertension control programmes. J Hum Hypertens 1996;10(Suppl. 1):S93-S94.
Hilleman DE, Mohiuddin SM, Lucas BD Jr, et al. Cost- minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther 1994;16:88-102.
Goldbaum M. Epidemiologia e serviços de saúde. Cad Saúde Públ 1996;12(Suppl. 2):95-8.
Sociedade Brasileira de Hipertensão. Consenso Brasileiro de Hipertensão. Campos do Jordão: Sociedade Brasileira de Hipertensão; 1998.
Bleecker E, Mark CL. Doenças Obstrutivas das Vias Aéreas. In: Barker LR, Burton JR, Zieve PD, orgs. Princípios de Medicina Ambulatorial. Porto Alegre: Artes Médicas; 1993.p.554-81.
Alonso Moreno FJ, Garcia Palencia M, Laborda Peralta M, Hermoso Lopez A, Lopez de Castro F. Analysis of pharmacologic costs in the treatment of arterial hypertension. Approximation to a cost-effectiveness study. Aten Primaria 1998;21:607-12.
Ramsey SD, Neil N, Sullivan SD, Perfetto E. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. J Am Board Fam Pract 1999;12:105-14.
Souza e Silva NA, Aguiar GR, Nogueira AR, Duarte MMT, Alves RHF. Importância Clínica dos Custos Diretos Hospitalares em Pacientes com Hipertensão Arterial em Tratamento num Hospital Universitário, Rio de Janeiro, Brasil. Rev Saúde Pública 1986;20:293-302.
Arredondo A, Damián T. Costos económicos en la producción de servicios de salud: del costo de los insumos al costo de manejo de caso. Salud Publica Mex 1997;39:117-24.
Dias da Costa JS, Fachinni LA. Utilização de serviços ambulatoriais em Pelotas: onde a população consulta e com que freqüência. Rev Saúde Pública 1997;31:360-9.
Piccini RX, Victora CG. How well is hypertension managed in the community? A population-based survey in a Brazilian city. Cad Saúde Públ 1997;13:595-600.
Svab I, Zaletel-Kragelt L. Frequent attenders in general practice: a study from Slovenia. Scand J Prim Health Care 1993;11:38-43.
Fowler G, Austoker J. Screening. In: Detels R, Holland WW, McEwen J, Omenn GS, editors. Oxford Textbook of Public Health. New York: Oxford University Press; 1997.p.1583-99.
Johannesson M. The cost-effectiveness of the switch towards more expensive antihypertensive drugs. Health Policy 1994;28:1-13.
Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmacoeconomics 2001;19:337-47.
Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure- lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000;356(9246):1955-64.
Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol 2001;37:1456- 60.
Psaty BM, Koepsell TD, Yanez ND, et al. Temporal patterns of antihypertensive medication use among adults, 1989 through 1992. JAMA 1995;273:1436-8.
Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: Do the JNC V recommendations affect prescribing? JAMA 1997;278:1745-8.
Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995;155:829-37.
Herrero JJA. Aplicacion del analisis coste-beneficio en la planificacion de los servicios sanitarios. Evidencia y equidad en la atecion perinatal. Barcelona: Masson AS; 1993.
Beulke R, Bertó DJ. Gestão de custos e resultados na saúde. Hospitais, clínicas, laboratórios e congêneres. São Paulo: Editora Saraiva; 1997.
Brook R. Managed care is not the problem, quality is. JAMA 1997;278:1612-4.
Campbell SM, Roland MO, Buetow SA. Defining quality of care. Soc Sci Med 2000;51:1611-25.
